News | October 17, 2006

Excellent Results Reported for CoreValve Device

A test designed to measure the durability of CoreValve’s ReValving device reached 200 million cycles, the company has reported. CoreValve’s chairman, CEO and founder, Dr. Jacques Seguin, says initial findings indicate its proprietary porcine pericardium aortic heart valve behaves, in vitro, better than tissue valves.

The valve is parts of its ReValving System for percutaneous aortic valve replacement (PAVR).

Condensing equivalent years of service life into months of testing, the company indicates it is applying advanced control and data-acquisition methods to monitor valve function and integrity. Testing is being conducted under strictly controlled regulatory guidelines.

"This event represents another mission-critical milestone toward marketing clearance in Europe as well as commencement of clinical trials in the United States," added Rob Michiels, president and COO of CoreValve


Related Content

News | Heart Valve Technology

May 9, 2023 — Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of ...

Home May 09, 2023
Home
News | Heart Valve Technology

February 28, 2023 — On Feb. 27, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to ...

Home February 28, 2023
Home
News | Heart Valve Technology

January 23, 2023 — Leakage of the mitral valve due to degenerative prolapse is a common condition known as primary ...

Home January 23, 2023
Home
News | Heart Valve Technology

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has given the approval to market to The Edwards ...

Home January 02, 2023
Home
News | Heart Valve Technology

December 29, 2022 — The Smidt Heart Institute at Cedars-Sinai was named a Mitral Valve Repair Reference Center, a ...

Home December 29, 2022
Home
News | Heart Valve Technology

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

Home December 14, 2022
Home
News | Heart Valve Technology

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

Home November 22, 2022
Home
News | Heart Valve Technology

October 18, 2022 — Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive ...

Home October 18, 2022
Home
News | Heart Valve Technology

October 18, 2022 — The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its ...

Home October 18, 2022
Home
News | Heart Valve Technology

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates ...

Home September 26, 2022
Home
Subscribe Now